Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Robert C. Doebele(Aurora University), Filippo de Braud(University of Milan), Christine H. Chung(Moffitt Cancer Center), Haruyasu Murakami(Shizuoka Cancer Center), Salvatore Siena(University of Milan), Manish R. Patel(University of Minnesota Medical Center), Myung‐Ju Ahn(Sungkyunkwan University), Na Cui(Shanghai University), Chia‐Chi Lin(National Taiwan University Hospital), Kōichi Goto(National Cancer Center Hospital East), Timothy R. Wilson, Edna Chow‐Maneval(Ignyta (United States)), Rafał Dziadziuszko(Gdańsk Medical University), Hans Prenen(Antwerp University Hospital), Byoung Chul Cho(Yonsei University), Susan Eng, Takashi Seto(National Hospital Organization Kyushu Cancer Center), Christos S. Karapetis(Clínica Alemana), Chao‐Hua Chiu(Taipei Veterans General Hospital), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Brian Simmons, Alice T. Shaw(Dana-Farber Cancer Institute), Matthew Krebs(Christie's), Young Kwang Chae(Northwestern University), Fabrice Barlési(Hôpital Nord), Thomas John(Austin Hospital), Yuichiro Ohe(National Cancer Center), Yu Li, Daniel Shao-Weng Tan(Memorial Sloan Kettering Cancer Center), Sang-We Kim(Asan Medical Center), Jürgen Wolf(University of Cologne), Todd Riehl, Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Hendrick-Tobias Arkenau(Sarah Cannon Research Institute), Ann Johnson(Ignyta (United States))
Cited by 537
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k